1.01
前日終値:
$1.021
開ける:
$0.99
24時間の取引高:
77,166
Relative Volume:
0.45
時価総額:
$32.94M
収益:
-
当期純損益:
-
株価収益率:
-2.9015
EPS:
-0.3481
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+32.81%
1か月 パフォーマンス:
+32.89%
6か月 パフォーマンス:
-18.55%
1年 パフォーマンス:
-65.76%
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
名前
Akari Therapeutics Plc Adr
セクター
電話
(646) 350-0702
住所
22 BOSTON WHARF ROAD, BOSTON
AKTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.01 | 33.30M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-18 | 開始されました | Maxim Group | Buy |
2019-01-04 | アップグレード | B. Riley FBR | Neutral → Buy |
2018-02-08 | 開始されました | B. Riley FBR, Inc. | Neutral |
2017-09-22 | アップグレード | William Blair | Mkt Perform → Outperform |
2017-05-31 | アップグレード | Chardan Capital Markets | Sell → Neutral |
2017-04-17 | 繰り返されました | Chardan Capital Markets | Sell |
2016-07-11 | 開始されました | Chardan Capital Markets | Sell |
すべてを表示
Akari Therapeutics Plc Adr (AKTX) 最新ニュース
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Akari Therapeutics appoints new CEO and board member - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Stock Titan
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
Akari Therapeutics Plc Adr (AKTX) 財務データ
Akari Therapeutics Plc Adr (AKTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):